Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18509
Country/Region: Kenya
Year: 2017
Main Partner: Amref Health Africa
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,468,513 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $179,103
Testing: HIV Testing and Counseling (HVCT) $182,608
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $140,220
Treatment: Adult Treatment (HTXS) $1,927,990
Treatment: Pediatric Treatment (PDTX) $38,592
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 475
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 207
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 39
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 16
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 441
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 212
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 39
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 18
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 550
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 262
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 18
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 10
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 325
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 162
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 26
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 14
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 475
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 238
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 45
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 23
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 21
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 11
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 6
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2018 5
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 454
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 2,756
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 1,178
GEND_GBV Number of people receiving post-GBV care 2018 3,934
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 79,982
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 738
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 3,120
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 3,766
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 2,215
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 657
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 457
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 686
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 456
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 207
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 143
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 247
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 237
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 64
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 92
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 2,590
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 638
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 686
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 8,046
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 2,712
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 8,015
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 4,259
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 16,048
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 9,517
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 1,140
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 1,063
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 3,004
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2018 4
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 12
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 9
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 8
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 11
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 13
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 22
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 26
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 172
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 100
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 12
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 13
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 179
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 193
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 139
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 668
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 476
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 1,215
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 468
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 1,640
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 1,155
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 170
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 138
HTS_TST Sum of Test Result disaggregates 2018 1,741
HTS_TST_POS By Test Result: Positive 2018 1,741
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 72
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 173
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 28
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 16
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 49
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 62
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 433
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 192
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 27
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 20
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 121
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 64
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 16
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 47
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 9
PMTCT_ART Already on ART at beginning of current pregnancy 2018 392
PMTCT_ART New on ART 2018 274
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 666
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 10,335
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 666
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 192
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 444
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 22
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 8
PMTCT_STAT By Age (Numerator): 15-19 2018 972
PMTCT_STAT By Age (Numerator): 20-24 2018 4,113
PMTCT_STAT By Age (Numerator): 25-49 2018 5,250
PMTCT_STAT By Number of known positives: 15-19 2018 27
PMTCT_STAT By Number of known positives: 20-24 2018 59
PMTCT_STAT By Number of known positives: 25-49 2018 306
PMTCT_STAT By Number of new negative: 15-19 2018 936
PMTCT_STAT By Number of new negative: 20-24 2018 3,965
PMTCT_STAT By Number of new negative: 25-49 2018 4,768
PMTCT_STAT By Number of new positives: 15-19 2018 9
PMTCT_STAT By Number of new positives: 20-24 2018 89
PMTCT_STAT By Number of new positives: 25-49 2018 176
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 10,335
PMTCT_STAT_den By Age (Denominator): <15-19 2018 972
PMTCT_STAT_den By Age (Denominator): 20-24 2018 4,113
PMTCT_STAT_den By Age (Denominator): 25-49 2018 5,250
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 17
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 153
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 17
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 90
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 277
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 277
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 17
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 160
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 10
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 90
TB_PREV By Age/Sex (Numerator): <15, Female 2018 38
TB_PREV By Age/Sex (Numerator): <15, Male 2018 21
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 1,541
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 826
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 2,426
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 2,426
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 2,696
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 42
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 23
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 1,711
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 920
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 2,696
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 28
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 371
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 22
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 258
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 679
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 679
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 28
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 371
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 22
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 258
TX_CURR Age/Sex: <1 2018 5
TX_CURR Age/Sex: <1-9 2018 290
TX_CURR Age/Sex: 10-14 Female 2018 93
TX_CURR Age/Sex: 10-14 Male 2018 52
TX_CURR Age/Sex: 15-19 Female 2018 218
TX_CURR Age/Sex: 15-19 Male 2018 135
TX_CURR Age/Sex: 20-24 Female 2018 684
TX_CURR Age/Sex: 20-24 Male 2018 372
TX_CURR Age/Sex: 25-49 Female 2018 7,388
TX_CURR Age/Sex: 25-49 Male 2018 3,969
TX_CURR Age/Sex: 50+ Female 2018 1,336
TX_CURR Age/Sex: 50+ Male 2018 717
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 15,269
TX_CURR Sum of age/sex disaggregates 2018 353
TX_NEW Breastfeeding status 2018 25
TX_NEW By Age/Sex: 1-9 2018 43
TX_NEW By Age/Sex: 10-14 Female 2018 16
TX_NEW By Age/Sex: 10-14 Male 2018 5
TX_NEW By Age/Sex: 15-19 Female 2018 36
TX_NEW By Age/Sex: 15-19 Male 2018 17
TX_NEW By Age/Sex: 20-24 Female 2018 119
TX_NEW By Age/Sex: 20-24 Male 2018 65
TX_NEW By Age/Sex: 25-49 Female 2018 1,317
TX_NEW By Age/Sex: 25-49 Male 2018 711
TX_NEW By Age/Sex: 50+ Female 2018 238
TX_NEW By Age/Sex: 50+ Male 2018 129
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 2,696
TX_NEW Pregnancy status 2018 249
TX_NEW Sum of Age/Sex disaggregates 2018 2,653
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 11,553
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 10,356
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 312
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 29
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 172
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 16
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 5,788
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 501
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,255
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 273
TX_PVLS Numerator: Indication: Routine 2018 9,527
TX_PVLS Numerator: Indication: Targeted 2018 829
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 17
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 44
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 168
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 386
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 347
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 30
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 193
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 17
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 6,446
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 562
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,638
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 320
TX_PVLS_den Denominator: Indication: Routine 2018 10,624
TX_PVLS_den Denominator: Indication: Targeted 2018 929
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 20
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 1,652
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 184
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 433
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 49
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 26
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,680
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 910
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,665
TX_RET Numerator by Status: Breastfeeding 2018 61
TX_RET Numerator by Status: Pregnant 2018 554
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 12,890
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 279
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 142
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 8,102
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 4,367
TX_RET_den Denominator by Status: Breastfeeding 2018 71
TX_RET_den Denominator by Status: Pregnant 2018 618
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 15,191
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 112
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 6
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 64
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 38
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 346
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 184
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 9,528
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 5,133
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 485
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 30
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 93
TX_TB_den Denominator: By Screen Result: Negative 2018 12,153
TX_TB_den Denominator: By Screen Result: Positive 2018 3,038
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 607
Cross Cutting Budget Categories and Known Amounts Total: $286,497
Gender: Gender Based Violence (GBV) $6,760
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $279,737